Viking Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) will attend multiple investor conferences in April 2026, holding management 1-on-1 meetings with investors and analysts. Events and dates: Raymond James Biotech/BioPharma Conference on April 14, 2026 in New York, and Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – VKTX
On the day this news was published, VKTX declined 1.97%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Details of the company's participation are as follows:
- Raymond James Biotech/BioPharma Conference 2026
Details: Viking management will participate in 1-on-1 meetings
Conference Date: April 14, 2026
Location:New York, NY - Piper Sandler Spring Biopharma Symposium 2026
Details: Viking management will participate in 1-on-1 meetings
Conference Date: April 16, 2026
Location:Boston, MA
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302739018.html
SOURCE Viking Therapeutics, Inc.